TetraAs(As4O6)Structure

* Source: Asan Medical Center, Korea Institute of Radiological and Medical Science, CHA hospital, college of veterinary medicine, SNU, KIST, Biotoxtech, Inje University, Catholic University of Korea, Handong University

Molucular Weight : 395.6
Molecular Structure : Diamond Structure

2,4,6,8,9,10 – Hexaoxa – 1,3,5,7 – tetraarsatricyclo[3.3.1.13,7]decane
As4O6 (Arsenic hexaoxide) API

<TetraAs tablet form>
Clinical Drug

<TetraAs® capsule (5mg) form>
Application progress of As as a drug (flow)
HISTORY OF AS
- Arsenic and arsenic compounds have used as a medicine or a toxin for 2000 years.
- An ointment containing arsenic is used as a therapeutic agent for dental disease, psoriasis, syphilis,
and rheumatic illness - Ancient Hippocrates age: : Realgar (AS2S3) and orpiment (AS2S2) were used as a drug for ulcers, pest, malaria and various cancers
- Other records that demonstrate the use of arsenic:
– India: Pregnant women have taken it to improve the health of their fetus
– Alps alpine region: Has been taken to invigorate vital energy
– India: Has been used as a dermal ointment
– China: Noted doctors including Jang Jung Gyeong, Pyeonjak, and Hwata used it as a drug for incurable diseases
– Korea: The noted doctor, Heo Jun, used arsenic to treat various incurable diseases - Used broadly as a medicinal product (to treat diseases) since the 18th century
Potassium carbonate solution of AS2O3 developed by Thomas Fowler (U.K) in 1786: Used as a drug for rheumatism, seizures (epilepsy), ulcers, and indigestion. In 1910, the founder of chemotherapy, Paul Ehrlich (toxin) invented salvarsan using arsenic (No. 606) and used it as a drug for syphilis. An organic arsenic compound, malarsoprol, is currently being prescribed to treat trypanosomiasis invading CNS. From 1940s, it was used as a therapeutic agent for CML until new treatment for CML was developed. - Reason for limited use of arsenic – ① Development of radiation therapy and other chemotherapies ② Known as a toxic substance with carcinogenic effects especially when used for long periods of time
- In 1992, Harbin medical University, China – Published the arsenic therapy for APL in an academic symposium in China
– Since Shen et al in China (Blood, 89; 3354-3360, 1999) reported that AS2O3 injections were effective in treating retinoic acid resistance in acute promyelocytic leukemia, a number of hospitals and researchers attempted to treat APL and various solid cancers with AS2O3 - In 1996, Shanghai Second medical University, China published in American Society of Hematology
- In 2000, U.S. FDA approved AS2O3 as an orphan medicinal product for the treatment of acute promyelocytic leukemia to all-trans retinoic acid
– Currently, arsenic is being studied in several countries including Korea and China - In Korea, CHEMAS has patent right on As4O6 and is taking a step to do clinical trial on As4O6
As anti-cancer drug
As2O3
- China – It was reported that AS2O3 is effective in treating APL in 1992
- U.S. FDA approved AS2O3 as an orphan medicinal product for the treatment of APL in 2000
– Cephalon (www.Cephalon.Com) – “TRISENOX” injections for intravenous administration - Limited use of arsenic’s advantages.
As4S4
- U.S. FDA approved As4S4 as a therapeutic agent for CML. (2002)
- It cannot be used for a long period of time because of its toxicity and its therapeutic effect on various solid cancers has not been proved sufficiently against leukemia
As4O6 (TetraAs)
- Solved the toxic problems and adverse effects of arsenic compounds
- Not accumulated in the human body and excreted within short period of time
- Almost no side effects in spite of long-term use
- Safety and effectiveness has been verified in pre-clinical trials (toxicity test) in Biotoxtech and phase 1 clinical trial in Asan Medical Center
- Huge therapeutic possibilities against various cancers
- Efficacy enhanced when used with other conventional cancer treatments
- Successfully completed pre-clinical and phase 1 clinical trials